Novartis, Par Hit With Pay-For-Delay Suit Over Exforge

Law360 (May 16, 2018, 7:59 PM EDT) -- Novartis Pharmaceuticals Corp. was able to keep a generic of its hypertension drug Exforge off the market for years by agreeing to let Par Pharmaceutical Inc. have six months of generic exclusivity, a deal that shunned competition and kept prices higher, according to a proposed class action filed in New York federal court Wednesday.

When Par filed its application to get its generic version of the drug approved, Novartis didn’t even sue for infringement, instead it immediately sought to reach an agreement outside of court, the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.